About daratumum ab
CD38-targeted monoclonal antibody
Used for
- Multiple myeloma, alone or with other cancer medicines.
- Light-chain amyloidosis, with other medicines.
Usual adult dose
Usually given under the skin every week initially, then less often according to the treatment regimen.
Common side effects
- Infusion or injection reactions, including breathing problems or rash.
- Infections, tiredness, nausea, diarrhoea, or constipation.
- Low blood-cell counts, including anaemia and low platelets.
- Injection-site reactions.
Important warnings
- Can cause serious allergic-type reactions during or after administration.
- May increase infection risk and lower blood-cell counts.
- Interferes with blood compatibility testing; tell the blood bank before transfusions.
- Can reactivate hepatitis B; screening and monitoring may be needed.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for three months after the last dose.
Breastfeeding
Breastfeeding is generally avoided during treatment and for three months after the last dose.
Interactions
- Can interfere with blood typing and crossmatching tests.
- Other cancer treatments may increase infection or low blood-cell risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.